Bavarian Nordic A/S said that the Oxford Vaccines Group, part of the University of Oxford, Department of Paediatrics, has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic’s MVA-BN Filo vaccine with the Ad26.ZEBOV vaccine from the Janssen Pharmaceutical Companies. The first volunteers have received their initial vaccine dose. Preliminary data from the first-in-human Phase 1 study, presented by Janssen in May to a U.S. Food & Dr...